Genedrive CEO Dr. Gino Miele talked about the company’s progress in rapid pharmacogenetic testing for emergency care at the Proactive One2One Investor Forum. Genedrive, a molecular diagnostics company based in Manchester, has developed two CE-IVD certified products designed to guide drug prescription in neonatology, neurology, and cardiovascular care.
Dr. Miele explained that the tests are the first to enable near-patient genetic analysis in critical settings, providing results in as little as 26 minutes, highlighting the importance of speed and ease-of-use.
Genedrive’s antibiotic-induced hearing loss test can prevent irreversible deafness in newborns, while its clopidogrel resistance test aims to reduce recurrent strokes. The company is seeing early commercial traction, with installations in UK hospitals and international sites, including Saudi Arabia.
Genedrive reported £0.5 million revenue in FY24 with significant near to medium term addressable market opportunities estimated at over £235 million annually. Genedrive aims to scale its impact in precision medicine worldwide.
#Genedrive #PrecisionMedicine #Pharmacogenetics #MolecularDiagnostics #NHSInnovation #GeneticTesting #NeonatalCare #StrokePrevention #HealthcareInnovation #DrugSafety
